Press Release
September 22, 2023

Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines

The Life Sciences team advised Orionis Biosciences on its multi-year collaboration agreement with Genentech to discover novel small molecule medicines for challenging targets in major disease areas.

Orionis will receive an upfront payment of $47 million and is eligible for development milestone payments, as well as commercial and net sales milestone payments that could exceed $2 billion and a tiered royalty upon sale of collaboration products.

Orionis Biosciences is a life sciences company pioneering the discovery of conditionally active drug modalities for life threatening diseases. These operate by leveraging induced molecular proximity and cooperativity mechanisms in unique fashion to gain novel target access, potency and precision.

The Goodwin team was led by Noelle Dubiansky, Alan Wang, Williams Collins, Adam Bellack and Elliot Horlick, with assistance from Susan Lee, Paul Jin, Kevin Walsh, Daniel Karelitz and Daniela Sanchez.

For more details, read the press release and coverage in BioSpace, Boston Business Journal and Fierce Biotech.